Comprehensive Study Guide on Lymphoma: Hodgkin's and Non-Hodgkin's Lymphoma Pathology and Care

Pathophysiology of Lymphoma

  • Lymphomas represent a group of cancers characterized by the abnormal overgrowth of mature lymphocytes within lymphoid cells and tissues.
  • There are two primary categories of lymphoma: Hodgkin's lymphoma and Non-Hodgkin's lymphoma.

Hodgkin's Lymphoma (HL)

  • Demographics and Risk Factors:
    • This form of lymphoma is most frequently observed in two specific age groups: teenagers/young adults and adults aged 5050 or older.
    • Potential viral etiologies include the Epstein-Barr virus (EBV), Human T-cell Leukemia Virus (HTLV), and Human Immunodeficiency Virus (HIV).
  • Pathological Markers and Spread:
    • A definitive diagnostic marker for Hodgkin's lymphoma is the presence of the Reed-Sternberg cell.
    • The disease typically originates in a single lymph node or a specific chain of lymph nodes.
    • The progression of the disease follows a predictable pattern as it spreads through the lymphatic system.

Non-Hodgkin's Lymphoma (NHL)

  • General Characteristics:
    • This is more common in adults over the age of 5050.
    • It is not considered a single disease but rather a broad category encompassing over 6060 distinct subtypes.
    • Subtypes are classified as either B-cell lymphomas or T-cell lymphomas, with B-cell types being the more prevalent.
  • Risk Factors and Incidence:
    • Incidence is higher in individuals who have undergone solid organ transplants or are taking immunosuppressant medications.
    • Those with HIV or exposure to environmental factors such as pesticides and insecticides are at increased risk.
    • Certain specific viruses and infections are also linked to higher incidence rates.
  • Progression:
    • Unlike Hodgkin's lymphoma, the spread of Non-Hodgkin's lymphoma is disorderly as it moves from node to node.
    • It has the potential to spread into the bone marrow.

Signs and Symptoms

  • Physical Manifestations:
    • The primary physical sign is the appearance of one or more large, painless lymph nodes.
  • "B Symptoms" (Specific to B-cell lymphoma):
    • Fever.
    • Night sweats.
    • Significant, unexplained weight loss.
  • Nonspecific Symptoms:
    • Persistent fatigue.
    • General malaise.
    • Itching (pruritus).

Labs and Diagnostics

  • Biopsy Procedures:
    • Lymph node biopsy: This is the essential test to differentiate between Hodgkin's lymphoma and Non-Hodgkin's lymphoma.
    • Bone marrow aspiration and biopsy: Performed to check for marrow involvement.
    • Cerebrospinal fluid biopsy: Indicated for Non-Hodgkin's lymphoma cases involving the Central Nervous System (CNS), the testes, or in patients with HIV-related lymphoma.
  • Laboratory Testing:
    • Complete Blood Count (CBC).
    • Electrolyte panel.
    • Kidney and liver function tests.
    • Cytogenetic studies: These analyze cells specifically for the presence of marker chromosomes.
    • Erythrocyte sedimentation rate (ESR).
    • Lactate dehydrogenase (LDH): This marker is specifically utilized in cases of Non-Hodgkin's lymphoma.
  • Imaging and Monitoring:
    • Computed Tomography (CT) scans of the neck, chest, abdomen, and pelvis are used for staging and localization.
    • Positron Emission Tomography (PET) scans are employed to monitor the progress of various therapies.

Treatment Modalities for Hodgkin's Lymphoma

  • Prognosis: This type responds very well to aggressive treatment, resulting in high long-term survival rates.
  • Treatment by Stage:
    • Early-stage disease: Typically managed with external radiation of the specific affected lymph nodes.
    • Moderate to severe disease: Managed through a combination of radiation therapy and chemotherapy.
  • Long-term Complications of Treatment:
    • Cardiovascular disease.
    • Secondary malignancies resulting from exposure to radiation therapy.
    • Restrictive lung disease.
    • Endocrine dysfunction, including infertility, hypothyroidism, and premature menopause.

Treatment Modalities for Non-Hodgkin's Lymphoma

  • Strategic Overview: Treatment protocols vary extensively based on the specific subtype, the patient's prognosis, and the current stage of the disease.
  • Available Options:
    • Chemotherapy.
    • Monoclonal antibodies.
    • Radiation therapy.
    • Radiolabeled antibodies.
    • Targeted therapies.
    • Novel therapies.
  • Chimeric Antigen Receptor (CAR) T-cell Therapy:
    • This process involves extracting T-cells from the patient’s own blood.
    • These cells are then "trained" or genetically modified to recognize the specific antigens on the patient’s cancer cells.
    • Once modified, they are infused back into the patient's circulation to actively identify and destroy cancer cells.
  • Cytokine Release Syndrome (Cytokine Storm):
    • A potential complication of CAR T-cell therapy that occurs over a 55 to 77 day period.
    • Symptoms include high fever, fatigue, body aches, hypotension (low blood pressure), edema, decreased urine output, mental status changes, nausea, and vomiting.

Nursing Interventions

  • Safety Precautions:
    • Implementation of neutropenic precautions due to low White Blood Cell (WBC) counts.
    • Implementation of bleeding precautions due to low platelet counts.
  • Supportive Care:
    • Anemia support: Administration of Packed Red Blood Cells (PBRCs) or epoetin alfa.
    • Management of nausea and vomiting using antiemetics.
    • Skin care management for patients undergoing radiation therapy.
    • Fluid and electrolyte management for gastrointestinal upset, including cases of constipation or diarrhea.